Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 5/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 1.00 |
| ▸ | HTR3B | O95264 | 4/20 | 1.00 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 1.00 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 1.00 |
| ▸ | HTR5A | P47898 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 0.66 |
| ▸ | HTR1D | P28221 | 1/20 | 0.66 |
| ▸ | HTR1B | P28222 | 1/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.59 |
| ▸ | HTR7 | P34969 | 3/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | HTR6 | P50406 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30870394 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL29688470 | 0.98 | HTR3A (0.96) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL15708159 | 0.98 | HTR3A (0.96) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL1781288 | 0.83 | HTR3A (0.71) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL29594813 | 0.82 | HTR3A (0.69) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL3534699 | 0.82 | HTR3A (0.69) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL15707949 | 0.81 | HTR3E (0.69) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL15534306 | 0.81 | HTR3A (0.69) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL15534114 | 0.80 | HTR3A (0.67) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL12806786 | 0.80 | HTR3A (0.72) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010179-A4 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK & CO INC (US) | 2009-05-06 | — | — | EP | claimed |
| EP-2010179-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120718-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | claimed |
| US-20250109103-A1 | (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | UNIWERSYTET JAGIELLONSKI (PL) | 2025-04-03 | — | — | US | disclosed |
| US-12139458-B2 | (2,5-dioxopyrrolidin-1-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases | UNIWERSYTET JAGIELLONSKI (PL) | 2024-11-12 | — | — | US | disclosed |
| CN-113272292-B | (2, 5-dioxopyrrolidin-1-yl) (phenyl) -acetamide derivatives and their use in the treatment of neurological diseases | 雅盖隆大学 | 2024-04-12 | — | — | CN | disclosed |
| US-20220073461-A1 | (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | WARSZAWSKI UNIWERSYTET MEDYCZNY (PL) | 2022-03-10 | — | — | US | disclosed |
| EP-3908580-A1 | (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | UNIWERSYTET JAGIELLONSKI (PL) | 2021-11-17 | — | — | EP | disclosed |
| CN-113272292-A | (2, 5-dioxopyrrolidin-1-yl) (phenyl) -acetamide derivatives and their use in the treatment of neurological diseases | 雅盖隆大学 | 2021-08-17 | — | — | CN | disclosed |
| EP-3428162-B1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-2170334-B1 | NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION | UNIV EMORY (US) | 2021-03-17 | — | — | EP | disclosed |
| CN-1178530-A | Compounds having an effect on 5-hydroxytryptamine related systems | LILLY CO ELI (US) | 1998-04-08 | — | — | CN | disclosed |
| EP-0773937-A1 | NOVEL ARYL PIPERAZINE-DERIVED PIPERAZIDE DERIVATIVES, METHODS FOR THEIR PREPARATION, THEIR USE AS DRUGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | PIERRE FABRE MEDICAMENT (FR) | 1997-05-21 | — | — | EP | disclosed |
| US-5627196-A | ANTIDEPRESSANTS AND ANTISEROTONIN AGENTS | ELI LILLY AND COMPANY (US) | 1997-05-06 | — | — | US | disclosed |
| US-5614523-A | INDOLYLOXY COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-03-25 | — | — | US | disclosed |
| US-5576321-A | ALKOXY-SUBSTITUTED INDOLES | ELI LILLY AND COMPANY (US) | 1996-11-19 | — | — | US | disclosed |
| WO-1996022290-A1 | COMPOUNDS HAVING EFFECTS ON SEROTONIN-RELATED SYSTEMS | ELI LILLY AND COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| EP-0722941-A2 | Compounds having effects on serotonin-related systems | ELI LILLY AND COMPANY (US) | 1996-07-24 | — | — | EP | disclosed |
| WO-1996002525-A1 | NOVEL ARYL PIPERAZINE-DERIVED PIPERAZIDE DERIVATIVES, METHODS FOR THEIR PREPARATION, THEIR USE AS DRUGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | PIERRE FABRE MEDICAMENT (FR) | 1996-02-01 | — | — | WO | disclosed |
| US-4695383-A | COPOLYAMIDE FROM A DIAMINODIPHENYL SULFONE | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1987-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073461-A1 | (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | TRPV5, P2RX5, TRPV1 | HTR3A 1673/4885HTR3E 1577/4885HTR3B 1735/4885 |
| US-12139458-B2 | (2,5-dioxopyrrolidin-1-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases | TRPV5, P2RX5, TRPV1 | HTR3A 1673/4885HTR3E 1577/4885HTR3B 1735/4885 |
| US-20250109103-A1 | (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | TRPV5, SCN5A, P2RX5 | HTR3A 1866/4885HTR3E 1775/4885HTR3B 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.